Sihem Khelifa

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock et al. · Journal of Clinical Oncology · 2017 · 487 citations

Medicine, Oncology, Pharmacology +17

Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies

Young Joo Jeon, Sihem Khelifa, Boris I. Ratnikov et al. · Cancer Cell · 2015 · 232 citations · Full text

Medicine, Molecular Biology, Oncology +14

Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery et al. · Journal of Clinical Oncology · 2017 · 35 citations

Medicine, Oncology, Pharmacology +17

HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome

Franck Boccara, Murielle Mary‐Krause, Valérie Potard et al. · Journal of the American Heart Association · 2020 · 22 citations · Full text

Medicine, Cardiology, Infectious Diseases +13

Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.

Andrea J. Bullock, Sunil R. Hingorani, Xionghua Wu et al. · Journal of Clinical Oncology · 2016 · 12 citations

Medicine, Oncology, Pharmacology +15